Achilles Therapeutics plc (ACHL)
Mar 20, 2025 - ACHL was delisted pending liquidation
1.480
0.00 (0.00%)
Inactive · Last trade price
on Mar 21, 2025
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Achilles Therapeutics stock had an average target of 4.00, with a low estimate of 2.00 and a high estimate of 6.00.
Analyst Consensus: Buy
* Price targets were last updated on Apr 5, 2024.
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock from 2 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +35.14% | Apr 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $6 | Strong Buy | Maintains | $11 → $6 | +305.41% | Apr 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.5 | Strong Buy → Sell | Downgrades | $7 → $0.5 | -66.22% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +643.24% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +643.24% | May 11, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.18
from -1.74
EPS Next Year
-0.12
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | n/a | n/a | n/a | |
| Avg | n/a | n/a | n/a | |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.19 | -0.13 | -2.88 | |
| Avg | -0.18 | -0.12 | -2.79 | |
| Low | -0.18 | -0.12 | -2.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.